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Cisplatin may have additive activity with temozolomide due to ablation of the DNA repair protein O
6-alkylguanine-DNA
alkyltransferase (MGMT). This phase I/II study determined recommended combination doses using the Continual Reassessment
Method, toxicities and antitumour activity in paediatric patients, and evaluated MGMT in peripheral blood mononuclear cells
(PBMCs) in order to correlate with haematological toxicity. In total, 39 patients with refractory or recurrent solid tumours (median
age B13 years; 14 pretreated with high-dose chemotherapy, craniospinal irradiation, or having bone marrow involvement) were
treated with cisplatin, followed the next day by oral temozolomide for 5 days every 4 weeks at dose levels 80mgm
 2/
150mgm
 2day
 1, 80/200, and 100/200, respectively. A total of 38 patients receiving 113 cycles (median 2, range 1–7) were
evaluable for toxicity. Dose-limiting toxicity was haematological in all but one case. Treatment-related toxicities were
thrombocytopenia, neutropenia, nausea-vomiting, asthenia. Hearing loss was experienced in five patients with prior irradiation to
the brain stem or posterior fossa. Partial responses were observed in two malignant glioma, one brain stem glioma, and two
neuroblastoma. Median MGMT activity in PBMCs decreased after 5 days of temozolomide treatment: low MGMT activity correlated
with increased severity of thrombocytopenia. Cisplatin–temozolomide combinations are well tolerated without additional toxicity to
single-agent treatments; the recommended phase II dosage is 80mgm
 2 cisplatin and 150mgm
 2 5 temozolomide in heavily
treated, and 200mgm
 2 5 temozolomide in less-heavily pretreated children.
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Despite increasing cure rates for many paediatric solid tumours,
metastatic disease and certain histologies carry a poor prognosis
and require new therapies. The use of new cytotoxic agents in
children is based on preclinical data and evaluations in adults
(Smith et al, 1998).
Temozolomide (Temodal
s, Temodar
s) is an orally adminis-
tered imidazotetrazinone second-generation alkylating agent that
is spontaneously converted to 5-(3-metyltriazen-1-yl)imidazole-4-
carboxamide (MTIC) at physiological pH, and therefore does not
require hepatic metabolism for activation. Its ability to cross the
blood–brain barrier is of special interest with respect to its activity
in central nervous system tumours (Patel et al, 2003). Temozolo-
mide has shown activity in preclinical models and in clinical trials
in patients with malignant gliomas and melanoma (Newlands et al,
1992; O’Reilly et al, 1993; Bleehen et al, 1995). Phase I and II
clinical trials in children and adolescents demonstrated tumour
responses in malignant gliomas (Estlin et al, 1998; Nicholson et al,
1998; Lashford et al, 2002).
The cytotoxicity and antitumour activity of temozolomide is
determined largely by methylation of DNA at the O
6-position
of guanine and the mismatch repair system, and is inversely
related to the activity of the DNA repair protein O
6-Alkyguanine-
DNA alkyltransferase (also known as O
6-methylguanine-DNA
methyltransferase (MGMT)) (Karran and Hampson, 1996; Pegg,
2000; Gerson, 2002; Tentori and Graziani, 2002). Modulation
of MGMT activity using pseudosubstrate inhibitors such as
O
6-benzylguanine (O
6BG) (Dolan et al, 1994) and more recently
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6-(4-bromothenyl)guanine (PaTrin-2) (Middleton et al, 2000a)
results in depletion of MGMT and increased sensitivity to DNA
alkylating or crosslinking agents, including temozolomide, car-
mustine, lomustine (Dolan et al, 1990; Plowman et al, 1994; Liu
et al, 1996; Wedge et al, 1996) and cisplatin (D’Atri et al, 1995;
Fishel et al, 2003). The latter is supported by the observation that
MGMT expressing cells are more resistant to the toxic effects of
cisplatin (Preuss et al, 1996). Cisplatin itself has been reported to
inactivate MGMT in HeLa cells (Wang and Setlow, 1989) and to
increase the sensitivity of human leukemic blasts to triazene
compounds (Piccioni et al, 1995). In Jurkat cells, decreased MGMT
activity was associated with the attenuation of expression of
MGMT mRNA (D’Atri et al, 2000). These observations have
suggested the possibility of a synergistic antitumour activity of
cisplatin with temozolomide and have led to a phase I clinical trial
of this combination in adult patients with advanced solid
malignancies (Britten et al, 1999). The combination was not
associated with enhanced toxicity and showed activity in patients
with carcinomas and sarcoma.
The present report presents the clinical results of a phase
I/II trial of the cisplatin–temozolomide combination in paediatric
patients with refractory or recurrent solid tumours. The objec-
tives were to define toxicity profiles and maximum tolerated
doses (MTDs), and to recommend a safe dose for phase II testing.
In order to perform a single study for two patient cohorts, heavily
and nonheavily pretreated patients, we chose a two stage, two
group continual reassessment method (CRM) design (O’Quigley
et al, 1999; O’Quigley and Paoletti, 2003). This model-based
adaptive experimental design is used in cancer trials as an
alternative to more conventional approaches because it provides a
combination of efficiency, safety and the use of informa-
tion obtained from all treated subjects. To date, there is little
experience on the use of the CRM in paediatric oncology trials. We
also undertook pharmacodynamic measurements of MGMT
activity in peripheral blood mononuclear cell (PBMC), because
of its possible role in toxicity and response to both cisplatin and
temozolomide, and to further examine the effect of cisplatin on
MGMT expression.
PATIENTS AND METHODS
Patient eligibility
Eligible patients were required to have a cytologically and/or
histologically confirmed diagnosis of a malignant solid tumour
(except brain stem tumours with clinical and radiological diag-
nosis), which was refractory or in relapse after standard treatment,
and/or for which no effective treatment was available. Two cohorts
were distinguished: less heavily treated (cohort A) and heavily
treated (cohort B) patients, the latter defined by prior craniospinal
irradiation (CSI) and/or high-dose chemotherapy with stem cell
rescue. Early in the study, the definition of cohort B was modified by
including patients with disease invasion to the marrow. Following
increased haematological toxicity, it was reasonable to assign them
to cohort B rather than to the initial cohort A. Patients were to be
between 6 months and 21 years of age with ECOG or Lansky
performance status of p2o rX50%, respectively, and a life
expectancy 46 weeks. Patients were required to have adequate
haematopoietic function, that is, neutrophils 41.0 10
9l
 1 and
platelets 4100 10
9l
 1, satisfactory hepatic function, that is,
bilirubin p1.5 upper normal limit (UNL), transaminases
p2.5 UNL, normal renal function including normal creatinine
clearance (470mlmin
 1/1.73m
2), audiogram pgrade 2, and no
radiotherapy or chemotherapy within the last 4 weeks before study
entry (6 weeks for nitrosoureas). Noninclusion criteria included
severe infection, symptomatic or evolutive intracranial hyperten-
sion, prior treatment with cisplatin X400mgm
 2.
Before study enrollment, complete medical history and clinical
examination, concomitant treatments, performance status, hae-
matologic and biochemical profile, clotting rates, creatinine
clearance, audiogram, ECG, chest-X-ray, and tumour target
assessment were ascertained. The study was conducted in six
centers in France in accordance with the Good Clinical Practices
and approved by the local Ethics Committee. Patient or parents or
the legal representative provided a written informed consent, and
patient assent was obtained, when appropriate.
Treatment
Cisplatin was purchased in vials of 100mgml
 1. The calculated
dose was diluted in 180mlm
 2 of normal saline. On day 0 of
treatment, 480mlm
 2 glucose 5% and electrolyte infusion solution
was administered prior to the cisplatin solution, which was given
over 180min simultaneously with 180mlm
 2 10% mannitol. This
was followed by 180mlm
 2 of normal saline and 10% mannitol.
Temozolomide (Temodal
s) was supplied by Schering-Plough
Laboratory (Levallois, France) as white-opaque, hard gelatin
capsules in strengths of 5, 20, and 100mg. The calculated doses
were rounded to the nearest 5mg. For children having difficulties
in swallowing, it was allowed to open the capsules and administer
the drug in apple juice or stewed fruit. Temozolomide was
administered p.o. on days 1–5 to patients who fasted for at least
4h before and 30min after each dose. Treatment was repeated
every 28 days.
Concomitant antiemetic treatments included ondansetron and
prednisone i.v. before cisplatin, and ondansetron p.o. on days 1–5
before temozolomide.
In the event of dose-limiting toxicity (DLT) (defined below), the
next cycle was delayed and the doses of cisplatin and temozolo-
mide reduced to the next lowest dose level. If neutrophils or
platelets at day 28 were o1.0 10
9 or o100 10
9l
 1, respectively,
the next cycle was delayed until recovery. In the case of hearing
loss or reduction of renal function (grade 3) or at a cumulative
cisplatin dose of 600mgm
 2, cisplatin treatment was discontinued
and treatment pursued with temozolomide alone.
Experimental study design
The overall objective was to determine for each cohort (A and B)
the recommended dose level for phase II testing by using a two
stage, two group CRM (O’Quigley et al, 1999; O’Quigley and
Paoletti, 2003). The MTD was defined as the dose level closest to
that producing a DLT in one patient in five on average. The
starting dose was 80mgm
 2 cisplatin and 150mgm
 2day
 1
temozolomide for 5 consecutive days (level 1), corresponding to
80% of the recommended dose in single treatments, with planned
dose escalation to 80/200 (level 2) and 100/200 (level 3),
respectively. Patients of both cohorts were initially treated as a
single group for dose escalation. After DLT occurred, the design
was switched to escalation/de-escalation according to the two
sample CRM model. After each new toxicity evaluation, the best
estimates of the MTD in the two groups were reassessed.
Information obtained at all levels was used in determining the
most appropriate level at which to treat the next patient or group
of patients. Early determination rules allowed the study to close
when, for either of the cohorts, inclusion would not result in
allocation to any level other than the one currently in use with a
probability close to 0.9 (O’Quigley and Reiner, 1998).
Toxicity and response evaluation
Toxicity, graded according to NCI common toxicity criteria
(NCI-CTC version 2.0), was assessed by clinical and biological
examinations at least weekly during a cycle, before each cycle and
at the end of treatment. Dose-limiting toxicity was defined as the
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with documented infection, persistent (more than 7 days) grade 4
neutropenia or grade 3 or 4 thrombocytopenia, thrombocytopenia
necessitating platelet transfusions for a period of more than 7 days,
or any nonhaematologic grade X3 toxicity (except vomiting in
the absence of adequate treatment, fever without infection,
mucocitis, or transient, that is, resolved to grade 1 or 0 at the
next treatment cycle in the case of hepatic toxicity). Antitumour
efficacy was assessed every two cycles and/or at the end of
treatment, according to the Response Evaluation Criteria in Solid
Tumour (RECIST) criteria of the National Cancer Institute
(Therasse et al, 2000). Responses were centrally reviewed by two
radiologists (DC and AG).
O
6-alkylguanine-DNA alkyltransferase activity in PBMCs
Blood samples were collected before cisplatin administration
(day 0), on day 1 before the first and on day 5 few hours
after the last temozolomide dose. Peripheral blood mononuclear
cells were isolated by Ficoll separation and resuspended in EDTA/
Tris buffer. O
6-alkylguanine-DNA alkyltransferase activity in cell-
free sonicates was determined by measuring the amount of
radioactivity transferred from [3H]methylated substrate DNA to
MGMT under protein-limiting conditions as previously described
(Watson and Margison, 2000). Specific activity was calculated as
fmolmg
 1 DNA in the PBMC extract. DNA content was determined
using the Picogreen dsDNA quantification kit (Molecular
Probes, Invitrogen, Paisley, UK) according to the manufacturer’s
instructions. For each set of samples, a pellet of human
lymphoblastoid cells (Raji) was included as an assay control and
the inter- and intra-assay precision for these samples was 4.6 and
3.5%, respectively, over the whole study. In a separate study,
replicate PBMC samples from the same volunteer gave an
intrasubject variation of 2.1%. The limits of quantification were
defined as 2.5fmol for MGMT and 0.1mgml
 1 for DNA content.
Several of the MGMT values in the post-temozolomide samples
were below the lower limit of quantification. In these cases
where the sample size was very small, but DNA was still
quantifiable, it was reasonable to calculate an MGMT specific
activity that would be the maximum possible value, rather than
presenting a zero value. While the result would give an under-
estimate of MGMT inactivation, it was considered more appro-
priate in the context of our hypothesis to present this rather than
an overestimate of inactivation. Statistical differences between
treatment and toxicity groups were assessed by the nonparametric
Mann–Whitney test.
RESULTS
Patients’ characteristics
Between May 2001 and June 2002, 39 patients (25 males, 14
females) were included and treated in the study; patients’
characteristics are summarised in Table 1. The median age was
12 years 8 months, patients had a median Lansky or ECOG
performance scores of 80% and 2, respectively. Predominant
tumour types were brain tumours, malignant mesenchymal
tumours and neuroblastoma. A total of 38 patients had received
prior chemotherapy and/or radiation therapy, one had surgical
tumour resection only. Five patients previously received cerebro-
spinal irradiation and 11 high-dose chemotherapy with autologous
stem cell rescue. Six patients had bone marrow metastases at study
entry. A total of 38 patients experienced between one and five
tumour relapses, one tumour was refractory to prior treatment.
Patient No. 007 enrolled in cohort B was deemed nonassessable for
toxicity, as he died due to tumour progression within 18 days after
treatment start.
Table 1 Characteristics of participants n¼39
Stratum
A without
HDCT
a/CSI
b/
BM
c (N¼25)
B HDCT/CSI/BM
(N¼14)
Overall (N¼39)
(%)
Age at study entry
Median 12 years 8
months
12 year 1 month 12 year 8 months
Range 1 year 10
months–19 years
11 months
4 years 5 months–
18 year 9 months
1 year 10 months–
19 years 11 months
Gender
Male 12 13 25 (64%)
Female 13 1 14 (36%)
Lansky performance status N¼12 N¼7 N¼19
Median (range) 80% (40–100%) 90% (80–100%) 80% (40–100%)
ECOG performance status N¼13 N¼7 N¼20
Median (range) 0 (0–3) 2 (1–3) 2 (0–3)
Diagnoses
Central nervous system
(CNS) tumous
N¼18
Malignant glioma 2 0 2
Anaplastic
ganglioglioma
10 1
Anapl. pleomorphic
xanto-astrocytoma
10 1
Brain stem glioma 7 0 7
Oligodendroglioma 1 0 1
Ependymoma 3 0 3
PNET 1 0 1
Medulloblastoma 0 2 2
Non-CNS tumours N¼21
Neuroblastoma 0 4 4
Rhabdomyosarcoma 1 1 2
Ewing tumours 1 2 3
Neurofibrosarcoma 1 1 2
Other sarcoma (indiff,
fusiforme)
33 6
Desmoplastic small
round cell tumour
10 1
Nephroblastoma 0 1 1
Retinoblastoma 1 0 1
Melanoma (CNS
metastases)
10 1
Tumour refractory at study
entry
10 1
Tumour relapsing 24 14 38
Median (range) 1 (1–3) 2 (1–5) 2 (1–5)
Prior therapy
Surgery only 1 0 1
Chemotherapy+
radiation therapy
16 9 25
Chemotherapy only 5 5 10
Radiation therapy only 3 0 3
Craniospinal irradiation 0 5 5
High-dose
chemotherapy
01 1 1 1
Bone marrow
involvement
06 6
Prior cisplatin N¼4 N¼4 N¼8
Median mgm
 2 (range) 245 (120–372) 300 (140–400) 245 (120–400)
Prior nephrectomy 0 2 2
Patients evaluable for
toxicity
25 13 38
aHigh-dose chemotherapy and peripheral stem cell rescue,
bCraniospinal irradiation,
cBone marrow involvement.
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In total, 39 patients received a total of 114 treatment cycles. In
cohort A, 73 cycles were administered in 25 patients at three dose
levels, and in cohort B, 42 cycles in 14 patients at two dose levels,
in both cohorts, between one to seven cycles per patient (median
2). Cycles were started at days 26–65 (median 29). In cohort A,
16% of cycles (12 out of 73) were delayed by more than 7 days,
12% (nine out of 73) were administered with a 17–40% reduced
temozolomide and/or cisplatin dose, in all but one due to
haematological toxicity. In cohort B, 17% of cycles (seven out of
41) were delayed, 7% (three out of 41) introduced with a 33%
reduced temozolomide dose. The median delay did not increase
with treatment duration.
Dose-limiting toxicity and MTD
In total, 25 patients were evaluable for toxicity in cohort A, and
13 in cohort B. In all but one, DLT during the first cycle was
haematological (Table 2). Overall, eight children experienced
persistent grade 3 thrombocytopenia, six of them needed platelet
transfusion support for a period of more than 7 days. Persistent
grade 4 neutropenia was noted in three patients. One child had
documented febrile infection during a persistent grade 4
neutropenia; one patient experienced grade 3 septicemia without
neutropenia. According to the CRM, the recommended doses for
less-heavily pretreated children were defined as cisplatin
80mgm
 2 and temozolomide 200mgm
 2day
 1 5, and cisplatin
80mgm
 2 and temozolomide 150mgm
 2day
 1 5 for heavily
pretreated children.
Dose escalation using the CRM
Figure 1 shows dose level and DLT in all treated patients. Patients
of both cohorts were initially treated as a single group for dose
escalation. The definition of cohort B was refined after patient 13.
This modified the group assignment of previously included
patients. The third DLT was no longer assigned to cohort A but
to cohort B. Running estimates of MTD for both cohorts were
updated; dose level 1 was recommended for patient 15 from cohort
A and level 2 for patient 16 from cohort B. Patient 28 was first
considered as a non-DLT, and dose level 3 was recommended. Had
patient 28 been correctly evaluated at that time, then the trial
would have come to a halt after patient 30. Ultimately, 25 and 14
patients were included in cohort A and B, respectively.
Haematologic toxicity
Haematological toxicity was common. Grade 3 or 4 neutropenia
was experienced by 72% (18 out of 25) of patients and in 45% (33
out of 73) cycles in cohort A and by 61% (eight out of 13) of
patients and in 35% (14 out of 40) cycles in cohort B. Grade 4
neutropenia was persistent for more than 7 days in nine of the 15
cycles and five of 11 patients experiencing grade 4 toxicity. Grade 3
thrombocytopenia occurred in 44% (11 out of 25) of patients and
in 25% (18 out of 73) cycles in cohort A and in 54% (seven out of
13) of patients and in 23% (nine out of 40) cycles in cohort B.
Persistent grade 3 thrombocytopenia was noted in 12 of the 27
cycles and 10 of 18 patients. The frequency of grade 3
thrombocytopenia was correlated with treatment dose levels. The
median nadir neutrophil and thrombocyte counts appeared during
the fourth week of the treatment cycle. Neither neutropenia nor
thrombocytopenia appeared cumulative.
Nonhaematologic toxicities
Nonhaematologic toxicities were mostly mild or moderate and
appeared independent of dose level and study cohort. Table 3
summarises grade 3 and 4 toxicities. The principle toxicities likely
to be related to study treatment were acute nausea and vomiting.
Despite premedication with ondansetron and corticoids, grade
1–2 nausea and/or vomiting occurred in 25% cycles and 39% of
patients, grade 3–4 in 5 and 11%, respectively. Grade 1–3 asthenia
was noted in 29% of patients. Three patients experienced four
episodes of grade 3 or 4 septicaemias, one of them during a grade 4
neutropenia. Grade 3 renal toxicity was observed in one patient
following intensive vomiting and subsequent dehydration. Toxicity
recovered to grade 1 at the end of the cycle.
Grade 2–3 hearing loss, evaluated with audiograms, was
noted in five (13%) patients at cumulative cisplatin doses of
Table 2 Dose-limiting toxicity at cycle one 38 patients
Dose level
Cohort A Cohort B
CDDP/TMZ mgm
 2day
 1 DLT/patients DLT DLT/patients DLT
80/150 1/6 Platelet transfusion 47 days 2/11 Thrombocytopenia G3 47 days
Platelet transfusion 47 days
80/200 3/11 Febrile neutropenia G4 and platelet transfusion
47 days
1/2 Neutropenia G4 and platelet
transfusion 47 days
Platelet transfusion 47 days
Septicaemia G3
100/200 3/8 Infection during neutropenia G4 and
thrombocytopenia G3 47 days
0
Platelet transfusion 47 days
Neutropenia G4 47 days
0
1
2
3
0 2 4 6 8 10121416182022242628303234363840
Patient no.
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o
s
e
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l *
Figure 1 Dose escalation according to the CRM. Patients in cohort A
(open diamond) and cohort B (closed square) were treated at the dose
levels indicated. Arrows indicate observed DLTs, * indicates that the
patient was not evaluable for toxicity and was excluded from the CRM.
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 2 (median 240mgm
 2). All these patients had
prior irradiation to a brain stem glioma, medulloblastoma
or ependymoma of the posterior fossa. None had signs of
renal toxicity. In total, 12 patients included in the study had
prior radiation therapy for a brain stem glioma or a tumour
of the posterior fossa. One girl with a brain stem glioma treated
with five cycles of cisplatin–temozolomide (400mgm
 2 cisplatin)
had a normal audiogram at the end of the study; the other
six patients had no audiogram evaluation after one or two
treatment cycles.
Several patients experienced adverse events, including grade
1–4 pain, headache and neurological alterations, that occurred in
general within the context of progressive disease (PD) and were
considered secondary to their cancer rather than a consequence of
cisplatin–temozolomide treatment.
Efficacy
Five patients experienced partial tumour response (PR). A patient
with an anaplastic ganglioglioma that had progressed previously
following temozolomide and radiation therapy experienced a PR
after six cycles at 80/150mgm
 2 and this continued after the
seventh cycle with temozolomide alone. Progression occurred 9
months after treatment start. An anaplastic pleomorphic xanto-
astrocytoma of the frontal lobe regressed after two cycles at
80/200mgm
 2. Surgical resection of the 2 2mm
2 tumour residue
after seven cycles determined no viable tumour cells. However,
shortly thereafter the patient relapsed and died due to tumour
progression. A PR was observed in a brain stem glioma after one
cycle at 100/200mgm
 2. Owing to ototoxicity, treatment con-
tinued with temozolomide alone until tumour progression
occurred 6 months after the study treatment start. In cohort B,
two boys with metastatic neuroblastomas previously treated with
high-dose chemotherapy and stem cell rescue and a second line of
chemotherapy, experienced nonconfirmed PR this being noted in
one of the patients by computer tomographical analysis after four
cycles. However, an mIBG scan had shown a slight reduction of
fixation sites at cycle 2, but PD at cycle 4. The other patient
experienced a PR by mIBG scintigraphy after two cycles; however,
he progressed with multiple new lesions at cycle 4.
Four patients had stable disease for at least 6 months treated
either with cisplatin–temozolomide or cisplatin–temozolomide
followed by temozolomide alone: two patients with a brain stem
glioma and one with a soft tissue clear cell sarcoma during 6
months, and one patient with a four times relapsing undiffer-
entiated sarcoma during 11 months.
Follow-up
Two patients with sarcomas and one with an ependymoma are
alive at 30, 28 and 27 months after study entry, respectively. One
patient was lost to follow-up after 7.6 months. After the end of the
study, six patients had continued treatment with temozolomide
alone for 2 to 5 months (median 3.5 months). These patients had
experienced PR (two) or stable disease or objective clinical
response (four) and were taken off study treatment due to
auditory toxicity (three cases) or maximal cumulative cisplatin
dose (three cases).
O
6-alkylguanine-DNA alkyltransferase activity in PBMCs
O
6-alkylguanine-DNA alkyltransferase activity was evaluable in 33
patients at least at one time point (Table 4). Baseline MGMT
activity (31 patients) varied from 2.8 to 52.5Fmmg
 1 DNA with a
Table 3 Grade 3 and 4 nonhaematological toxicities
NCI grade Cycles (N¼113) Imputability
a Total (%) Patients (N¼38) %
General: asthenia/fatigue G3 4 2 3.5 4 10.5
Gastrointestinal: nausea-vomiting G3 3 3 2.7 1 2.6
G4 3 1 2.7 3 7.9
Infection
Infection during neutropenia G3 1 0 0.9 1 2.6
Septicaemia G3 2 1 1.8 1 2.6
G4 1 1 0.9 1 2.6
Urinary tract infections G3 1 0 0.9 1 2.6
Pain
Headache G4 1 0 0.9 1 2.6
Unspecified G3–4 2 0 1.8 2 5.3
Neurological
Neurological alteration G3–4 3 0 2.7 3 7.9
Reduced vigilance, hallucination G3 1 0 0.9 1 2.6
Intracranial hypertension G3 1 0 0.9 1 2.6
Infection
Infection in neutrocytopenia G3 1 1 0.9 1 2.6
Septicaemia G3 2 1 1.8 1 2.6
G4 1 1 0.9 1 2.6
Urinary tract infections G3 1 0 0.9 1 2.6
Renal insufficiency
Creatinaemia G3 1 1 0.9 1 2.6
Ototoxicity (audiogram)
Hypacusis G3 2 2 1.8 2 5.3
aEvents considered certain, probably or possibly related to study medication.
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smedian of 12.8Fmmg
 1 DNA. O
6-alkylguanine-DNA alkyltransfer-
ase in 27 patients after cisplatin administration ranged from 3.0 to
44.7Fmmg
 1 DNA with a median of 12.4Fmmg
 1 DNA; MGMT in
25 patients on day 5 ranged from o0.4 to 31.3Fmmg
 1 DNA with a
median of 4.4Fmmg
 1 DNA. There was a wide range of change in
MGMT levels following treatment in individual patients. After
cisplatin, while the mean and median MGMT activities were 116
and 102% of baseline levels, respectively, indicating no overall
marked change, individual activities varied from 29 to 309% of
baseline levels. Interestingly, in the two patients exhibiting the
highest pretreatment levels (42.2 and 52.5Fmmg
 1 DNA) there was
significant reduction after cisplatin treatment to 12.4 and
27.2Fmmg
 1 DNA, respectively. Significant (B50%) reductions
were also seen in four other patients with much lower pretreatment
levels. Substantial (450%) increases in MGMT activity were seen
in five patients. After treatment with temozolomide for 5 days,
the mean and median MGMT activities were at most 65 and 34%
of baseline levels, respectively, indicating an overall substantial
inactivation of MGMT (P¼0.0004; Mann–Whitney test). How-
ever, again, individual levels varied considerably, ranging from o5
to 310% of pretreatment levels. Thus, in a total of 25 patients with
evaluable samples at baseline and at day 5, 17 patients (68%) had
MGMT depletion of more than 50%, two patients (8%) had MGMT
depletion of less than 50%, three patients (12%) had an increase of
MGMT of more than 50% and three patients (12%) had an increase
of less than 50%. The greatest increases were seen in those patients
with the lowest pretreatment levels, but the reasons for this are
not evident. Depletion was seen at all dose levels tested and was
independent of the treatment group, response or any other
parameters.
In order to assess if there was any correlation between MGMT
levels at baseline or after cisplatin–temozolomide treatment and
haematological toxicity, we excluded data from Patient No. 007,
who was not evaluable for toxicity. Patients experiencing
thrombocytopenia grade 0–2 had higher levels of MGMT at
baseline (median 14.5Fmmg
 1, range 3.1–52.5Fmmg
 1) and after
CISTEM treatment (median 5.5Fmmg
 1, range 0.6–31.3Fmmg
 1)
than patients with grade 3 toxicity (median 6.7Fmmg
 1, range
2.8–15.9Fmmg
 1 at baseline; P¼0.0158; and median 2.2Fmmg
 1,
range 0.4–7.8Fmmg
 1 at day 5; P¼0.0123; Figure 2). There was no
correlation between MGMT and neutropenia: grade 0–2 patients
had a median value of 12.8Fmmg
 1 (range 3.1–42.2Fmmg
 1) and
grade 3–4 patients a median of 12.3Fmmg
 1 (range 2.8–
52.5Fmmg
 1) at baseline and a median of 4.6Fmmg
 1 (range
0.4–31.3Fmmg
 1) and 6.1Fmmg
 1 (1.3–12.3Fmmg
 1), respec-
tively, on day 5.
In summary, temozolomide treatment for 5 days depleted
MGMT in peripheral mononuclear cells in at least 76% of patients
and low MGMT activity was correlated with severe thrombocyto-
penia during the first treatment cycle.
DISCUSSION
The rationale for combining cisplatin and temozolomide was based
on the potential for improved antitumour activity. Both have
marked activity in paediatric malignancies; cisplatin is part of
many protocols for solid tumours and temozolomide has shown
activity in malignant gliomas (Newlands et al, 1992; Estlin et al,
1998). Both agents target DNA, although they kill cells by different
mechanisms: temozolomide via methylation at the O
6 position of
guanine and the subsequent action of the mismatch repair system,
whereas cisplatin produces DNA crosslinks preferentially via
reaction at the N7 positions of guanine and adenine (O’Dwyer
et al, 1997). Despite this, there is increasing evidence that
inactivators of MGMT can enhance the toxicity of cisplatin (Fishel
et al, 2003). In addition, preclinical studies suggested that cisplatin
can attenuate the expression of MGMT (D’Atri et al, 2000)
resulting in increased sensitivity to temozolomide and additive
tumour growth inhibition (Piccioni et al, 1995). Although a clinical
combination of temozolomide with cisplatin might be beneficial in
Table 4 MGMT activity in peripheral blood mononuclear cells
ATase SA (Fmlg
 1) % Activity remaining following
Patient
number Day 0 Day 1 Day 5 Cisplatin Temozolomide
25# 2.8 7.8 276
2 3.1 3.7 5.5 119 177
24# 3.9 11.9 4.1 309 107
7 3.9 5.4 0.85 140 22
20 3.9 12.1 310
13# 4.3 5.1 0.4 120 9
36 4.9 3.6 74
39 5.9 6.8 1.1 115 19
9 7.1 9.0 127
10# 7.5 3.1 3.1 41 41
38# 7.8 3 1.3 38 17
6# 8.2 9.0 0.7 110 9
15 8.3 14.3 9.0 173 109
4 10.7 10.9 2.6 102 25
17# 11.0 5.4 4.3 49 39
12 12.8 5.5 6.2 43 48
21 12.9
31# 13.1 0.6 5
30# 13.5 35 2.9 259 22
22 15.5 33.3 12 215 77
28 15.9 22.4 141
14 15.9 14.7 5.5 92 35
3 17.5 15.4 10.1 88 57
18 19.2 44.7 4.6 233 24
16# 19.3 13.4 3.3 69 17
23 21.2 18.4 87
29 25.3 33.3 132
11# 27.7 25.2 4.4 91 16
33 28.4 24 31.3 85 110
19 42.2 12.4 14.5 29 34
34 52.5 27.2 12.3 52 24
Mean 14.4 15.4 6.4 116 65
Median 12.8 12.4 4.4 102 34
Range 2.8–52.5 3.0–33.3 o0.4–31.3 29–309% 5–310%
Values in bold are maximum values for sample in # marked patient.
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Figure 2 MGMT specific activity (SA: Fmmg
 1 DNA) in PBMC cells
at baseline and depletion at day 5 of cisplatin–temozolomide treatment
in samples of patients evaluable for toxicity in relation to grade of
thrombocytopenia experienced during the first treatment cycle. The
median values for each group are shown as a thick horizontal bar.
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sterms of tumour responses, it is also possible that normal tissue
toxicities may be increased, and this needed to be examined in
phase I studies in the paediatric setting.
Based on the preclinical findings, in the present paediatric trial,
cisplatin was administered as a 3-h infusion prior to temozolomide
for 5 days. As the toxicity profiles of cisplatin and temozolomide
are very distinct, we started the dose escalation of each agent at
80% of their single agent dose. This selection was appropriate as
the results showed that the combination of the two drugs did not
potentiate existing toxicities of the individual agents. The DLT of
cisplatin–temozolomide after the first treatment cycle in children
and adolescents was haematologic. This was consistent with the
phase I data of the cisplatin–temozolomide combination in adult
malignancies (Britten et al, 1999), but also similar to paediatric
data for temozolomide given as a single agent (Estlin et al, 1998;
Nicholson et al, 1998; Lashford et al, 2002). Subsequently, the MTD
of the cisplatin–temozolomide combination for both cohorts (A
and B) were similar to those of the previous studies. Britten et al
(1999) determined the recommended dose for the adult phase II
study as temozolomide 200mgm
 2day
 1 5 days and cisplatin
75mgm
 2 every 28 days. In contrast to our study, cisplatin was
scheduled at day 1 beginning 4h after the first of five daily doses of
temozolomide. The paediatric phase I studies of the Children’s
Cancer Group and the UK group using temozolomide as single
agent had stratified according to prior CSI and determined the
MTD of temozolomide at 215mgm
 2/day 5 administered every
21 days or 200mgm
 12/day 5 every 28 days for children and
adolescents in the non-CSI group and 180mgm
 2day
 1 5 in the
CSI-treated group (Estlin et al, 1998; Nicholson et al, 1998). Both
of these paediatric dose-finding studies did not include patients
after high-dose chemotherapy or with bone marrow involvement
at study entry in the heavily pretreated cohort. These patients
often have reduced thrombocytopoiesis, which may have
contributed to the lower dose of temozolomide tolerated by our
patients in cohort B.
Non-haematological toxicity in children was mostly mild or
moderate and did not differ from those known for both single
agents. Owing to the potential renal and auditory toxicity of
cisplatin, the study limited the maximal cumulative dose to
600mgm
 2, including prior treatment. Nevertheless, we observed
five patients with hearing loss of more than 50db at 4000 or
2000Hz at lower doses. It is worth noting that all five patients had
prior irradiation to the brain including a significant radiation dose
to the ear region. Our findings confirmed a reduced maximal
tolerated cumulative dose of cisplatin in these children. We did not
consider that the association of temozolomide had any contribu-
tion to this toxicity. In the study of Britten et al, three out of 15
patients experienced grade 3 hearing loss and three further
patients grade 2 tinnitus without subjective hearing loss (Britten
et al, 1999). There was no additional information given on the
prior treatment of these patients.
Both temozolomide and cisplatin have potential emetic
effects. Nausea-vomiting were observed in half of the patients
despite premedication; however, they were mostly mild to
moderate and manageable with standard antiemetic treatment.
The lack of additive emetic effects of the cisplatin–temozolomide
combination had been also reported in adult patients (Britten
et al, 1999). In addition, Britten et al had performed pharmaco-
kinetic studies that showed no pharmacokinetic interac-
tions between the two drugs. Thus, cisplatin and temozolomide
can be combined at their MTD without additive toxicity profiles;
however cumulative toxicity of cisplatin limits the duration of this
combination treatment.
A distinguishing feature of this dose finding study was the use
of the CRM. The CRM firstly enabled us to perform a single trial
with dose-escalations in two stratified groups. The design allows
for a more efficient use of the data so that both groups can be
evaluated simultaneously, sharing information and thereby
improving overall identification of both MTDs. Secondly, the
CRM is expected to provide a more accurate estimate of both
MTDs since they are identified on the basis of all collected
observations. The CRM determined level 2 for the nonheavily
pretreated children and level 1 for the heavily pretreated children
as recommended doses for the combination. The classical dose
escalation would have determined level 1 and minus 1, respec-
tively, which are below the single MTD doses of temozolomide
for these cohorts. Thus, the classical design would have been too
conservative in its estimate of MTDs. Discussion is ongoing
about the accuracy of the dose-finding methodologies used in
phase 1 trials (Korn et al, 1999; O’Quigley, 1999). The currently
ongoing phase II trial in malignant glioma, which is using the
doses defined by the CRM, will give further clarification for this
combination treatment.
Encouraging tumour responses were observed in children with
recurrent gliomas and brain stem gliomas. The response of an
anaplastic ganglioglioma in a girl who was one of three siblings
of a family with a Li–Fraumeni syndrome with an identified
p53 mutation (R273H) was interesting as she had progressed
previously with temozolomide and irradiation treatment. P53
mutations and lack of p21-mediated cell arrest have been
suggested to render cancer cells resistant to temozolomide
(Tentori et al, 1998; Hirose et al, 2001; Bocangel et al, 2002),
although the data on the implication of p53 in temozolomide
resistance are not consistent (Middlemas et al, 2000). Recently, the
results of phase II studies combining cisplatin and temozolomide
in adult patients with malignant gliomas were published. For
20 patients with recurrent glioblastomas and 13 with anaplastic
astrocyctomas, Silvani et al (2003) reported progression-free
survival at 12 months of 14 and 17%, respectively. Brandes et al
(2004) reported responses in relapsing chemotherapy-naive
glioblastomas in 10 of 49 assessed patients and 34% progression-
free survival at 6 months. These findings and those of the present
study have resulted in a phase II study in children and adolescents
with newly diagnosed and relapsing high-grade gliomas (SFCE
and UKCCSG).
A number of clinical trials involving temozolomide and related
alkylating agents have included assessments of the levels of
expression and depletion of the DNA repair protein MGMT and
the majority of studies have examined effects in PBMCs as a
surrogate tissue. In the present study, baseline PBMC MGMT
activity exhibited a very wide range with values between 2.8 and
52.5 (mean 14.171.0) Fmmg
 1 DNA. This was somewhat higher
than previous values (Middleton et al, 2000b: range 2.2–25.6,
mean 12.6) but similar to other ongoing studies (range 2.3–51.6,
mean 15.5: GPM unpublished results). Another study of adult
patients has reported a range of B0.6 to B19Fmmg
 1 DNA and a
much lower mean of 6.974.7Fmmg
 1 DNA (Tolcher et al, 2003).
Some of these differences may be a consequence of the age or
disease status of the study groups.
Cisplatin had no overall effect on PBMC MGMT levels, and
although we did observe a significant reduction in those patients
with high baseline MGMT activity, reductions were also seen in
some patients with intermediate activity, while there were
increases in others. To our knowledge, no evaluation of MGMT
depletion in PBMCs in patients following cisplatin exists to date so
that these observations remain to be confirmed. At present, our
results using the current doses and schedule do not support the
possibility that MGMT depletion might be consistently achieved by
cisplatin in a way that could be exploited clinically, although
further studies are warranted.
O
6-alkylguanine-DNA alkyltransferase levels in PBMCs were
reduced in most patients at the end of temozolomide treatment at
all dose levels although it must be noted that part of this depletion
might be due to a delayed effect of cisplatin. Previous studies
reporting MGMT in adult PBMCs have also shown a range of
extents of depletion by temozolomide. A variety of dose regimen
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sand schedules have been examined but complete depletion of
MGMT has been observed in very few patients and very wide
variations in depletion are always observed (Lee et al, 1994; Gander
et al, 1999; Middleton et al, 2000b; Tolcher et al, 2003). The
reasons for this have yet to be established.
We did not attempt to correlate the initial levels or depletion of
MGMT in PBMCs with tumour response, since this was a phase I
combination trial including patients with different malignancies
and multiple prior lines of treatment. However, regarding toxicity,
we found that the grade of thrombocytopenia during cycle 1 was
correlated with low baseline levels of MGMT though this was not
evident for neutropenia. Although our evaluations are in a limited
number of samples and need to be confirmed and extended by
further studies, they are supported by previous studies. Thus,
lower MGMT activities in PBMCs have been associated with
increased haematological toxicity in a phase II study of
temozolomide in adult melanoma patients (Middleton et al,
2000b) and inactivation of MGMT was correlated with haemato-
logical toxicity in a phase I study of temozolomide (Tolcher et al,
2003). Nevertheless, to address the questions of MGMT inactiva-
tion by cisplatin in relation to tumour responses and toxicities, it
would be necessary to undertake larger studies, ideally in direct
comparison with equivalent numbers of patients receiving
temozolomide alone.
CONCLUSION
The combination of cisplatin and temozolomide is well tolerated in
children and adolescents, generating no toxicity greater than that
of the single agents. The antitumour activity observed in the
current study led to the ongoing evaluation in a phase II clinical
setting in children with newly diagnosed and recurrent malignant
gliomas.
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